Literature DB >> 16741311

Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides.

Marie Boyd1, Susan C Ross, Jennifer Dorrens, Natasha E Fullerton, Ker Wei Tan, Michael R Zalutsky, Robert J Mairs.   

Abstract

UNLABELLED: Recent studies have shown that indirect effects of ionizing radiation may contribute significantly to the effectiveness of radiotherapy by sterilizing malignant cells that are not directly hit by the radiation. However, there have been few investigations of the importance of indirect effects in targeted radionuclide treatment. Our purpose was to compare the induction of bystander effects by external beam gamma-radiation with those resultant from exposure to 3 radiohaloanalogs of metaiodobenzylguanidine (MIBG): (131)I-MIBG (low-linear-energy-transfer [LET] beta-emitter), (123)I-MIBG (potentially high-LET Auger electron emitter), and meta-(211)At-astatobenzylguanidine ((211)At-MABG) (high-LET alpha-emitter).
METHODS: Two human tumor cell lines-UVW (glioma) and EJ138 (transitional cell carcinoma of bladder)-were transfected with the noradrenaline transporter (NAT) gene to enable active uptake of MIBG. Medium from cells that accumulated the radiopharmaceuticals or were treated with external beam radiation was transferred to cells that had not been exposed to radioactivity, and clonogenic survival was determined in donor and recipient cultures.
RESULTS: Over the dose range 0-9 Gy of external beam radiation of donor cells, 2 Gy caused 30%-40% clonogenic cell kill in recipient cultures. This potency was maintained but not increased by higher dosage. In contrast, no corresponding saturation of bystander cell kill was observed after treatment with a range of activity concentrations of (131)I-MIBG, which resulted in up to 97% death of donor cells. Cellular uptake of (123)I-MIBG and (211)At-MABG induced increasing recipient cell kill up to levels that resulted in direct kill of 35%-70% of clonogens. Thereafter, the administration of higher activity concentrations of these high-LET emitters was inversely related to the kill of recipient cells. Over the range of activity concentrations examined, neither direct nor indirect kill was observed in cultures of cells not expressing the NAT and, thus, incapable of active uptake of MIBG.
CONCLUSION: Potent toxins are generated specifically by cells that concentrate radiohalogenated MIBG. These may be LET dependent and distinct from those elicited by conventional radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16741311

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  51 in total

1.  Evaluation of new iodinated acridine derivatives for targeted radionuclide therapy of melanoma using 125I, an Auger electron emitter.

Authors:  Maryline Gardette; Janine Papon; Mathilde Bonnet; Nicolas Desbois; Pierre Labarre; Ting-Dee Wu; Elisabeth Miot-Noirault; Jean-Claude Madelmont; Jean-Luc Guerquin-Kern; Jean-Michel Chezal; Nicole Moins
Journal:  Invest New Drugs       Date:  2010-06-22       Impact factor: 3.850

2.  Molecular and cellular radiobiological effects of Auger emitting radionuclides.

Authors:  Amin I Kassis
Journal:  Radiat Prot Dosimetry       Date:  2010-11-24       Impact factor: 0.972

Review 3.  Clinical radioimmunotherapy--the role of radiobiology.

Authors:  Jean-Pierre Pouget; Isabelle Navarro-Teulon; Manuel Bardiès; Nicolas Chouin; Guillaume Cartron; André Pèlegrin; David Azria
Journal:  Nat Rev Clin Oncol       Date:  2011-11-08       Impact factor: 66.675

4.  Demonstration of a radiation-induced bystander effect for low dose low LET beta-particles.

Authors:  Rudranath Persaud; Hongning Zhou; Tom K Hei; Eric J Hall
Journal:  Radiat Environ Biophys       Date:  2007-06-07       Impact factor: 1.925

Review 5.  Radiation-induced bystander signalling in cancer therapy.

Authors:  Kevin M Prise; Joe M O'Sullivan
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

6.  Computational modeling of cellular effects post-irradiation with low- and high-let particles and different absorbed doses.

Authors:  Adriana Alexandre S Tavares; João Manuel R S Tavares
Journal:  Dose Response       Date:  2012-03-19       Impact factor: 2.658

7.  Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.

Authors:  Jürgen Grünberg; Dennis Lindenblatt; Holger Dorrer; Susan Cohrs; Konstantin Zhernosekov; Ulli Köster; Andreas Türler; Eliane Fischer; Roger Schibli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-24       Impact factor: 9.236

Review 8.  Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.

Authors:  Michael R Zalutsky; David A Reardon; Oscar R Pozzi; Ganesan Vaidyanathan; Darell D Bigner
Journal:  Nucl Med Biol       Date:  2007-05-11       Impact factor: 2.408

9.  Radiolabeling and in vitro evaluation of (67)Ga-NOTA-modular nanotransporter--a potential Auger electron emitting EGFR-targeted radiotherapeutic.

Authors:  Eftychia Koumarianou; Tatiana A Slastnikova; Marek Pruszynski; Andrey A Rosenkranz; Ganesan Vaidyanathan; Alexander S Sobolev; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2014-04-02       Impact factor: 2.408

Review 10.  Therapeutic radionuclides: biophysical and radiobiologic principles.

Authors:  Amin I Kassis
Journal:  Semin Nucl Med       Date:  2008-09       Impact factor: 4.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.